Nancy L. Lewis Appointed as Chief Scientific Officer at NCCN

The National Comprehensive Cancer Network (NCCN) has appointed Dr. Nancy L. Lewis as the new Chief Scientific Officer. Dr. Lewis is an accomplished biomedical researcher with extensive experience in clinical trials addressing solid tumors and hematologic malignancies. Previously, she served at Novartis Pharmaceuticals and held academic positions. Her education includes degrees from recognized universities and training at premier cancer centers.

As Chief Scientific Officer, Dr. Lewis will lead the NCCN's clinical trials, enhance the quality and accessibility of cancer care, and support various NCCN programs, including the Oncology Research Program and Clinical Practice Guidelines. Her role will involve contributions to NCCN's educational and policy initiatives globally. Dr. Lewis takes over from Dr. Crystal S. Denlinger, who became NCCN's CEO. She is set to begin her role in May 2026.

The NCCN is a not-for-profit alliance focused on improving cancer research and patient care worldwide. Dr. Lewis' appointment aims to foster innovation and improve patient outcomes in oncology.